Key trials of platinum agents in advanced/metastastic BC with gBRCA1/2 mutations
| Trial | Population | Phase | Treatment arms | Outcomes |
|---|---|---|---|---|
| TNT (NCT00532727) [46] | Advanced/metastatic TNBC | III | Carboplatin vs. docetaxel | Overall population:ORR 31.4% (carboplatin) vs. 34% (docetaxel); PFS 3.1 months (carboplatin) vs. 4.4 months (docetaxel); OS 3.1 months (carboplatin) vs. 4.4 months (docetaxel)gBRCA1/2 subgroup:ORR 68% (carboplatin) vs. 33% (docetaxel); PFS 12.8 months (carboplatin) vs. 12 months (docetaxel) |
| TBCRC009 (NCT00483223) [47] | Metastatic TNBC | II | Cisplatin vs. carboplatin | Overall population:ORR 25.6% (study population); ORR 32.6% (cisplatin) vs. 18.7% (carboplatin)gBRCA1/2 subgroup:ORR 54.6% |
BC: breast cancer; gBRCA1/2: germline mutations in the BReast CAncer (BRCA) 1/2 gene; ORR: objective response rate; OS: overall survival; PFS: progression-free survival; TNBC: triple negative breast cancer